U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated…
Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events…
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with…
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with…
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 26,…
New Study Provides Insight into the Bioavailability of Medical Cannabis Formulations for Therapeutic TreatmentNEW YORK, June 26, 2025 (GLOBE NEWSWIRE)…
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuitySafety profile consistent with…
REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB, the “Company”), a global biotech company specializing in the…
REYKJAVIK, Iceland, June 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the…
ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy® 2 mg (the trade name for neffy® in…